<DOC>
	<DOCNO>NCT01130337</DOCNO>
	<brief_summary>This study evaluate disease free survival rate combination capecitabine [ Xeloda ] oxaliplatin ( XELOX ) trastuzumab [ Herceptin ] patient resectable gastric cancer . The combination Xeloda ( orally , 1000 mg/m2 day 1-14 every cycle ) Herceptin ( intravenously , 8 mg/kg load dose , 6 mg/kg day 1-14 every cycle ) administer three cycle prior surgery resect tumor . If complete resection , R0 microscopic residual tumor R1 achieve , patient continue three cycle XELOX Herceptin completion 12 month treatment Herceptin alone . Oxaliplatin administer intravenously dose 130 mg/m2 day 1 every cycle . The anticipated time study drug 12 month .</brief_summary>
	<brief_title>A Study Capecitabine Xeloda Combination With Trastuzumab Herceptin Oxaliplatine Patients With Resectable Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult patient 18 year age Locally advance resectable HER2positive gastric esophagogastric junction adenocarcinoma ( Sievert type I , II , III ) Measurable ( RECIST criterion ) assessable disease ECOG performance 02 Life expectancy 12 week Immeasurable lesion evidence disease Previous chemotherapy radiotherapy gastric neoplasm kind previous surgical resection tumor ( except diagnostic laparoscopy ) Concomitant heart disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>